首页> 外文期刊>Leukemia Research Reports >Total body irradiation-based haploidentical hematopoietic stem cell transplantation using posttransplant cyclophosphamide after administration of inotuzumab ozogamicin: A case report
【24h】

Total body irradiation-based haploidentical hematopoietic stem cell transplantation using posttransplant cyclophosphamide after administration of inotuzumab ozogamicin: A case report

机译:基于总体辐射的血份造血干细胞移植使用后翻版蛋白ozogamicin后使用后翻译环磷酰胺:案例报告

获取原文
       

摘要

Owing to the poor prognosis of relapsed or refractory acute lymphoblastic leukemia (ALL), hematopoietic stem cell transplantation (HSCT) followed by effective salvage therapy is required. Inotuzumab ozogamicin (INO) was developed for ALL refractory to standard chemotherapy. However, previous reports suggest that sinusoidal obstruction syndrome (SOS) risk increases in patients with HSCT receiving INO, especially with dual alkylating agents. We report a case of relapsed Philadelphia chromosome-negative B-ALL where the patient underwent haploidentical HSCT using fludarabine/total body irradiation conditioning and posttransplant cyclophosphamide. Successful engraftment was achieved without SOS development.
机译:由于复发或难治性急性淋巴细胞白血病(全部)的预后差,需要造血干细胞移植(HSCT),然后是有效的挽救疗法。 为所有难治性的标准化疗开发了Inotuzumab ozogamicin(Ino)。 然而,之前的报道表明,HSCT接受INO的HSCT患者的正弦梗阻综合征(SOS)风险增加,特别是用双烷基化剂。 我们举报了一种复发的费城染色体阴性B-所有患者使用氟拉马尼/全身照射调理和后翻转环磷酰胺的患者进行了患者的患者。 没有SOS发展,成功的植入就实现了成功的植入。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号